Lupin gains Health Canada approval for biosimilar Pegfilgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Pegfilgrastim
Lupin and Axantia enter into license-, supply- and technology-sharing agreement for Pegfilgrastim
Under the terms of the agreement, Axantia will register, distribute and market biosimilar Pegfilgrastim drug product in certain…
US FDA accepts biologics license application from Lupin for pegfilgrastim biosimilar
This BLA expands the company's oncology portfolio
Biocon Biologics receives EU GMP Certification for multiple Biosimilars manufacturing facilities in…
These facilities are used for the manufacture of DS and DP for Biosimilars: Bevacizumab, Trastuzumab, Pegfilgrastim and secondary…
USFDA approves Biocon’s sBLA for Pegfilgrastim new manufacturing facility
Expanded capacity will enable greater patient access globally